A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Phase 1 Completed 27 enrolled Memorial Sloan Kettering Cancer Center Bristol-Myers Squibb · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to find out what effects, good or bad, the addition of nivolumab or the combination of nivolumab plus ipilimumab to typical chemotherapy has on the treatment of advanced high-grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin. The typical chemotherapy treatment is Carboplatin and Paclitaxel.

Timeline

Start: 2017-08-04
Primary completion: 2025-12-04
Completion: 2025-12-04

Publications

Moufarrij S, Friedman CF, Freeman S, Green H, Abu-Rustum NR, Broach V, Chi DS, Cohen S, Gardner G, Grisham RN, Iasonos A, Leitao MM Jr, Long K, Park K, Tew W, Wibmer A, Zhou Q, Aghajanian C, Weigelt B, Zamarin D, O'Cearbhaill RE. A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer. Gynecol Oncol. 2025 Dec;203:97-104. doi: 10.1016/j.ygyno.2025.10.020. Epub 2025 Oct 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipilimumab	Monoclonal antibody	1 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	480 mg	Intravenous
Background	Carboplatin	Small molecule	6 unknown	Intravenous
Background	Paclitaxel	Small molecule	80 mg/m2	Intravenous

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications